Trial Profile
Protocol ATI001-102 Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Combination With Nivolumab in Subjects With Recurrent or Progressive Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs INXN 2001 (Primary) ; Nivolumab (Primary) ; Veledimex (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics; ZIOPHARM Oncology
- 01 Jun 2022 Results published in the Neuro-Oncology
- 01 Oct 2021 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.